Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)

• Published in: Lancet neurology Vol. 10; no. 7; pp. 618 - 625
• Main Authors: Macdonald, R Loch, Higashida, Randall T, Keller, Emanuela, Mayer, Stephan A, Molyneux, Andy, Raabe, Andreas, Vajkoczy, Peter, Wanke, Isabel, Bach, Doris, Frey, Aline, Marr, Angelina, Roux, Sébastien, Kassell, Neal
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.07.2011; Elsevier Limited
• Subjects: Anemia; Aneurysm; Cardiovascular system; Cerebral infarction; Clinical trials; Coiling; Dioxanes - therapeutic use; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Endothelin receptors; Female; Glasgow Outcome Scale; Humans; Hypotension; Lung; Male; Morbidity; Mortality; Neurology; Pharmaceuticals; Pyridines - therapeutic use; Pyrimidines - therapeutic use; Risk assessment; subarachnoid hemorrhage; Subarachnoid Hemorrhage - complications; Subarachnoid Hemorrhage - drug therapy; Subarachnoid Hemorrhage - mortality; Subarachnoid Hemorrhage - surgery; Sulfonamides - therapeutic use; Surgical Instruments; Tetrazoles - therapeutic use; Treatment Outcome; Vasoconstriction; Vasospasm, Intracranial - drug therapy; Vasospasm, Intracranial - etiology; Vasospasm, Intracranial - mortality; Vasospasm, Intracranial - prevention & control

Clazosentan, an endothelin receptor antagonist, significantly and dose-dependently reduced angiographic vasospasm after aneurysmal subarachnoid haemorrhage (aSAH). We investigated whether clazosentan reduced vasospasm-related morbidity and all-cause mortality. In this randomised, double-blind, place...